The Swissmedic representative spoke to Professor Simon P. Hoerstrup, Co-Director of the Center, about cooperation between researchers and the regulatory authority and the potential benefits for people with illnesses.
Wyss Zurich, Swissmedic’s Innovation Office, which was founded in 2022, and the ATMP Division headed by Julia Djonova share the goal of developing innovations to the highest standard of quality as quickly and safely as possible. ATMP is the abbreviation for advanced therapy medicinal product and the term is applied to products based on genes, tissues or cells. “As a regulatory authority, we’ve been in touch with Wyss Zurich right from the outset”, says Julia Djonova. But today’s visit is for a discussion, not an inspection. “We want to hear about researchers’ needs and find out how and where we can support and assist them.”
